Labcorp (LH) Expected to Post Quarterly Earnings on Thursday

Labcorp (NYSE:LH) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Labcorp to announce earnings of $4.79 per share and revenue of $3.7094 billion for the quarter. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 9:00 AM ET.

Labcorp (NYSE:LH) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the business earned $3.84 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. On average, analysts expect Labcorp to post $18 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Labcorp Trading Up 1.4%

LH stock opened at $301.03 on Tuesday. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The firm has a market cap of $24.68 billion, a P/E ratio of 26.66, a P/E/G ratio of 1.97 and a beta of 0.89. Labcorp has a 1-year low of $244.52 and a 1-year high of $301.79. The business’s 50 day moving average is $270.30 and its 200-day moving average is $269.49.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio is 25.51%.

Insiders Place Their Bets

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. This trade represents a 5.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at $1,930,637.74. This trade represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 6,991 shares of company stock valued at $1,796,696 in the last 90 days. 0.84% of the stock is currently owned by insiders.

Institutional Trading of Labcorp

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LH. Invesco Ltd. raised its stake in shares of Labcorp by 7.1% during the fourth quarter. Invesco Ltd. now owns 1,391,978 shares of the medical research company’s stock worth $349,220,000 after buying an additional 91,867 shares during the last quarter. Corient Private Wealth LLC raised its position in shares of Labcorp by 242.5% during the 4th quarter. Corient Private Wealth LLC now owns 92,438 shares of the medical research company’s stock valued at $23,191,000 after acquiring an additional 65,451 shares during the last quarter. Vident Advisory LLC raised its position in shares of Labcorp by 23.9% during the 4th quarter. Vident Advisory LLC now owns 21,961 shares of the medical research company’s stock valued at $5,510,000 after acquiring an additional 4,232 shares during the last quarter. Beacon Pointe Advisors LLC lifted its stake in shares of Labcorp by 15.0% in the 4th quarter. Beacon Pointe Advisors LLC now owns 1,812 shares of the medical research company’s stock valued at $455,000 after purchasing an additional 237 shares during the period. Finally, EP Wealth Advisors LLC acquired a new position in shares of Labcorp in the 4th quarter valued at $514,000. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on LH. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Robert W. Baird lifted their price target on shares of Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Bank of America upped their price objective on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Finally, Weiss Ratings raised shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus price target of $315.33.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.